Not true about fosphenytoin is:
**Core Concept**
Fosphenytoin is a water-soluble prodrug of phenytoin, used for the treatment and prevention of seizures. It has a different pharmacokinetic profile compared to phenytoin, making it a more favorable option in certain clinical scenarios.
**Why the Correct Answer is Right**
Fosphenytoin is a prodrug that is converted to phenytoin in the body. This conversion occurs through the action of phosphatases, which remove the phosphate groups from fosphenytoin to form phenytoin. The conversion rate is not affected by the patient's renal function, making fosphenytoin a useful option in patients with renal impairment.
**Why Each Wrong Option is Incorrect**
**Option A:** This statement is true about fosphenytoin, as it is a water-soluble prodrug that is more easily administered intravenously compared to phenytoin.
**Option B:** This statement is true about fosphenytoin, as it has a more favorable pharmacokinetic profile compared to phenytoin, allowing for faster and more predictable administration.
**Option C:** This statement is true about fosphenytoin, as it is used for the treatment and prevention of seizures in a variety of clinical settings.
**Clinical Pearl / High-Yield Fact**
It is essential to note that the conversion of fosphenytoin to phenytoin is not affected by the patient's renal function, making it a useful option in patients with renal impairment. However, the dosing of fosphenytoin should still be adjusted according to the patient's clinical response.
**Correct Answer: D**